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Abstract
Spinal muscular atrophy (SMA) is caused by low survival motor neuron (SMN) levels and patients represent a clinical
spectrum due primarily to varying copies of the survival motor neuron-2 (SMN2) gene. Patient and animals studies show that
disease severity is abrogated as SMN levels increase. Since therapies currently being pursued target the induction of SMN, it
will be important to understand the dosage, timing and cellular requirements of SMN for disease etiology and potential
therapeutic intervention. This requires new mouse models that can induce SMN temporally and/or spatially. Here we
describe the generation of two hypomorphic Smn alleles, Smn
C-T-Neo and Smn
2B-Neo. These alleles mimic SMN2 exon 7
splicing, titre Smn levels and are inducible. They were specifically designed so that up to three independent lines of mice
could be generated, herein we describe two. In a homozygous state each allele results in embryonic lethality. Analysis of
these mutants indicates that greater than 5% of Smn protein is required for normal development. The severe hypomorphic
nature of these alleles is caused by inclusion of a loxP-flanked neomycin gene selection cassette in Smn intron 7, which can
be removed with Cre recombinase. In vitro and in vivo experiments demonstrate these as inducible Smn alleles. When
combined with an inducible Cre mouse, embryonic lethality caused by low Smn levels can be rescued early in gestation but
not late. This provides direct genetic evidence that a therapeutic window for SMN inductive therapies may exist.
Importantly, these lines fill a void for inducible Smn alleles. They also provide a base from which to generate a large
repertoire of SMA models of varying disease severities when combined with other Smn alleles or SMN2-containing mice.
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Introduction
The survival motor neuron (SMN) gene is ubiquitously expressed
and encodes an essential protein that is required by all cells [1].
Low levels of SMN cause proximal spinal muscular atrophy
(SMA), an autosomal recessive disease, and a common genetic
cause of infant mortality [2,3]. It is pathologically characterized by
selective loss of lower motor neurons within the spinal cord,
causing progressive muscle atrophy due to denervation. Proximal
muscles within the limbs and trunk are more affected than distal
muscle groups, but ultimately all muscles succumb to denervation
causing paralysis, respiratory deficiency and ultimately death.
Clinically, SMA is heterogeneous and has been divided into
three major groups based upon age at onset and achieved motor
milestones [4,5]. Genetically SMA is homogenous in that all forms
of the disease are caused by homozygous deletion, rare subtle
mutations, or gene conversion of the survival motor neuron-1 (SMN1)
gene with concurrent retention of a linked paralog, survival motor
neuron-2 (SMN2) [2,6,7]. Both SMN genes reside in a duplicated
genomic region at 5q13, are transcribed, translated and 99.9%
identical [2,8,9]. The key difference is a single, translationally
silent nucleotide transition (C to T) at the +6 position within exon
7 that functionally distinguishes SMN1 from SMN2 and prevents
SMN2 from fully compensating for SMN1 loss [2,9,10]. SMN1
contains a ‘‘C’’ nucleotide and produces full-length SMN trans-
cripts (FL-SMN). In contrast, SMN2 contains a ‘‘T’’ nucleotide and
primarily produces transcripts that lack exon 7 (SMND7) and a
small amount of FL-Smn. This is due to the simultaneous
disruption of an ASF/SF2 exon splice enhancer (ESE) and
creation of an exon splice silencer (ESS) in SMN2 [11,12].
The SMN2 copy number in an individual can vary from one to
six and it is this variability that is mainly responsible for the clinical
spectrum seen in SMA patients [13]. Since every SMA patient
has at least one functioning SMN2 gene, it has become a target
for therapeutic interventions, and most pre-clinical studies
have focused on up-regulating SMN levels by some means
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SMN-dependent therapies is an understanding of when, where
and how much SMN induction is required, and how this might
change for the various clinical forms of SMA. The dosage, timing
and cellular requirements of SMN in different tissues should not be
overlooked as there is mounting evidence in humans and mice that
suggest non-motor neuron targets such as heart, autonomic and
vascular systems may require consideration [25,26,27,28]. Al-
though some data is already available and demonstrates a
therapeutic window of opportunity to affect a benefit for severe
SMA mice [15,17,29], a new panel of mice is required in which
SMN can be induced temporally and/or spatially to refine and
extend current results.
In this study, we report the generation and characterization of
two Smn progenitor alleles, Smn
C-T-Neo and Smn
2B-Neo. They were
designed to stimulate Smn exon 7 alternative splicing, which
normally does not occur in the mouse [30,31]. Smn
C-T-Neo and
Smn
2B-Neo are severe hypomorphs that cause embryonic lethality
when in a homozygous state due to the presence of a loxP- flanked
neomycin (neo) gene resistance cassette that hinders Smn expression.
However, in the presence of Cre recombinase, the embryonic
lethality can be rescued by neo excision, while still maintaining Smn
exon 7 alternative splicing via our introduced mutations. In vitro
and in vivo experiments demonstrate the utility of these mice to be
used as inducible Smn alleles when combined with Cre transgenic
lines. Using a tamoxifen-inducible Cre line we show that
embryonic lethality can be rescued early in gestation but not late.
As a final point, the Smn
C-T-Neo and Smn
2B-Neo lines were specifically
designed to be progenitor alleles, so that potentially three useful
lines of mice could be generated from each targeting event.
Importantly, these lines alter the endogenous Smn locus so they
mimic SMN2 exon 7 alternative splicing and the situation of SMA
patients, which is reduction of Smn protein levels, not absence of
protein. When used as inducible Smn alleles, they increase Smn
levels under the normal regulation of the endogenous locus, while
still mimicking SMN2 splicing.
Results
Generation and germline transmission of Smn
C-T-Neo and
Smn
2B-Neo alleles
Based on our previous studies we designed two replacement
vectors, p(Smn
C-T-Neo) and p(Smn
2B-Neo) and introduced two
different mutations into the endogenous Smn locus by homologous
recombination. The first mimics human SMN2 and is a C-T
transition at position 6 of exon 7, referred to hereafter as the C-T
mutation. The second mutation alters the central portion of the
ESE where hTra2-Beta1 binds Smn exon 7 (GGA to TTT), and we
refer to this mutation as the 2B mutation [32] (Figure 1A). It is
known that this binding site is important for SMN exon 7
processing [33]. For both replacement vectors the positive
selection cassette, pgk-neo, was inserted into the unique BamHI
site ,180 bp distal to exon 7 in the antisense orientation to Smn
transcription. This was specifically done as an additional way to
potentially hinder Smn processing. We also flanked (‘‘floxed’’) the
pgk-neo cassette with loxP sites so that it could be excised with Cre
recombinase in future experiments to leave the endogenous locus
with a minimal amount of alteration.
Homologous recombinant embryonic stem cell clones were
identified by Southern blot hybridization (Figure 1B) and two
independent clones for each construct used to generate chimeras.
Germline transmission was confirmed through direct sequenc-
ing of Smn exon 7 PCR products (Figure 1C). We refer to
these progenitor lines as Smn
C-T-Neo (official name Smn1
tm2Cdid) and
Smn
2B-Neo (official name Smn1
tm1Cdid) as they retain the floxed pgk-neo
selection cassette within Smn intron 7. All subsequent experiments
Figure 1. Generation of mutant Smn alleles. (A) Gene targeting strategy to introduce the C-T and 2B mutation into Smn exon 7 using the gene
targeting vectors pSmnC-T-Neo and pSmn2B-Neo. (B) Southern blot analysis of BamH I and Pst I digested DNA from neo resistant ES cell clones
identified homologous recombinants. Two clones from each were used to perform blastocyst injections. (C) Germline transmission of Smn
C-T-Neo and
Smn
2B-Neo alleles were determined by direct sequencing of Smn exon 7 PCR products from heterozygous mice. The C-T mutation corresponds to the
nucleotide transition within exon 7 of the SMN2 gene. The 2B mutation corresponds to a mutation within the splice enhancer region 2B, changing
GGA to TTT [32].
doi:10.1371/journal.pone.0015887.g001
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mice for at least three generations.
Smn
C-T-Neo and Smn
2B-Neo alleles express very small
amounts of Smn
To evaluate the effects of C-T-Neo and 2B-Neo mutations on
Smn exon 7 processing, all major organs including spinal cord and
skeletal muscle from postnatal tissues of heterozygous mice were
analyzed by reverse transcription-polymerase chain reaction (RT-
PCR). Smn
C-T-Neo/WT mice produced both FL-Smn and D7Smn
transcripts as did Smn
2B-Neo/WT mice (data not shown). We
performed a series of intercrosses for each allele during the course
of this study. Of 229 and 281 pups genotyped at weaning from
Smn
C-T-Neo/WT and Smn
2B-Neo/WT intercrosses, respectively, none
were found to be homozygous (Table 1). To identify when during
development Smn
C-T-Neo/C-T-Neo and Smn
2B-Neo/2B-Neo embryos were
dying, we performed a series of timed matings. For Smn
C-T-Neo/WT
intercrosses at 9.5 days post-coitum (E9.5), a total of 58 em-
bryos were analyzed. While near mendelian ratios of wild type
(Smn
WT/WT), heterozygous (Smn
C-T-Neo/WT) and homozygous mu-
tants (Smn
C-T-Neo/C-T-Neo) were identified by genotyping, develop-
mental delays of homozygous mutant Smn
C-T-Neo/C-T-Neo embryos
(11/58; 19%) were visible (Table 1 and Figure 2, panels a–h).
Although at E12.5 we could still detect Smn
C-T-Neo/C-T-Neo embryos
(5/56; 9%), it was clear that all were developmentally delayed and
some were undergoing resorption (Table 1 and Figure 2, panels
i–p). By E15.5 only wild type and heterozygous Smn
C-T-Neo/WT
embryos were present (Table 1).
Our results for embryo analysis from Smn
2B-Neo/WT intercrosses were
more dramatic. We analyzed 84 embryos at E9.5 and while we could
detect Smn
2B-Neo/2B-Neo homozygotes (14/84; 17%), these embryos were
more developmentally delayed than the Smn
C-T-Neo/C-T-Neo embryos and
were starting to be reabsorbed (Table 1 and Figure 2 panels a’–h’). At
E12.5 all Smn
2B-Neo/2B-Neo homozygotes that we could detect were dead
and at different levels of resorption (Table 1 and Figure 2, panels i’–p’).
By E15.5 only wild type and heterozygous Smn
2B-Neo/WT embryos were
present (Table 1).
The embryonic lethality of Smn
C-T-Neo/C-T-Neo and Smn
2B-Neo/2B-Neo
embryos occurs later than Smn
D7/D7 embryos, who die at E7.5 [34,35].
This suggested that a small amount of FL-Smn was being produced. To
determine whether this was the case, we analyzed RNA from E9.5 wild
type, heterozygous and homozygous Smn
C-T-Neo and Smn
2B-Neo embryos
by RT-PCR. Both FL-Smn and D7Smn were produced from
heterozygous and homozygous Smn
C-T-Neo and Smn
2B-Neo embryos in
contrast to wild type Smn embryos (Smn
WT) (Figure 3A). Furthermore,
the Smn
C-T-Neo allele consistently produced more transcripts that
contained Smn exon 7 than the Smn
2B-Neo allele. Direct sequencing of
the FL-Smn amplicon from Smn
C-T-Neo/C-T-Neo embryos identified only
the mutant ‘‘T’’ nucleotide at position +6o fSmn exon 7, as would be
expected from homozygous mutant embryos (Figure 3B). Likewise, FL-
Smn amplicons from Smn
2B-Neo/2B-Neo embryos only expressed the 2B
(TTT) mutation (data not shown).
To quantify the amount of FL-Smn and D7Smn transcripts that
were produced in each of the genotypes from our intercross
experiments, we designed two novel taqman assays for use in
quantitative reverse transcription PCR (qRT-PCR). The first assay
specifically detected Smn exon 7 in the presence of either the wild
type, C-T or 2B mutation with similar efficiency. The second
assay detected D7Smn transcripts. The values of FL-Smn from
our Smn
C-T-Neo and Smn
2B-Neo genotypes were compared to the
expression of Smn
WT E9.5 embryos derived from the same
intercross to reduce variability. Overall, the amount of FL-Smn
varied with our different genotypes (Figure 3C and Table 2).
Smn
C-T-Neo/C-T-Neo embryos produced 2065% FL-Smn, whereas
Smn
2B-Neo/2B-Neo embryos produced 1563% and these values were
not statistically significant from each other (p=0.43). This
indicated that each Smn
C-T-Neo and the Smn
2B-Neo allele produced
,10% and ,7.5% FL-Smn transcripts, respectively. These results
are consistent with Smn
C-T-Neo/WT (62612%) and Smn
2B-Neo/WT
(5967%) embryos, if you consider that ,50% of FL-Smn
transcripts are derived from the Smn
WT allele (Figure 3C and
Table 2).
We also quantified the amount of D7Smn from our Smn
C-T-Neo
and Smn
2B-Neo genotypes by comparing them to D7Smn trans-
cripts derived from spinal cord samples of Smn
D7/WT mice [34].
Smn
2B-Neo/2B-Neoembryos expressed the greatest amount of D7Smn
transcripts, whereas the Smn
C-T-Neo/WT embryos expressed the least
(Figure 3A and 3C). Using this data in conjunction with our FL-
Smn data we were able to generate a FL-Smn: D7Smn ratio for each
genotype using the DDCt values. The ratio for Smn
D7/WT mice was
approximately equal to 1.0 (1.02260.018) and served as a control.
The wild type allele (WT) only produces transcripts that contain
Smn exon 7, whereas the Smn
D7 allele only produces transcripts that
lack exon 7 due to the absence of the exon in the genome of this
allele [34]. In comparison, Smn
C-T-Neo/WT mice produced about 12-
fold more (11.9860.929) FL-Smn than D7Smn transcripts.
However, in homozygous embryos (Smn
C-T-Neo/C-T-Neo) the ratio
was almost equal to 1.0 (0.98960.068) and this is consistent with
Table 1. Genotype of Smn
C-T-Neo and Smn
2B-Neo intercross progeny.
Age # of Litters Total Pups +/+ (%) +/2 (%) 2/2 (%) unknown identity (%) x
Smn
C-T-Neo intercross progeny
1 month 39 229 80 (35) 144 (63) 0 (0) 5 (2) 83.6 (P,0.001)
E15.5 5 33 15 (45) 18 (54.5) 0 (0) 0 (0) 13.9 (P,0.001)
E12.5 8 56 14 (25) 28 (50) 5 (9) 9 (16) 5.17 (P.0.05)
E9.5 6 58 16 (27.5) 22 (38) 11 (19) 9 (15.5) 1.5 (P,0.05)
Smn
2B-Neo intercross progeny
1 month 44 281 109 (39) 170 (60.5) 0 (0) 2 (0.7) 98.5 (P,0.001)
E15.5 6 4 4 2 2( 5 0 ) 2 2( 5 0 ) 0( 0 ) 0( 0 ) 2 2( P ,0.001)
E12.5 7 63 5 (8) 36 (57) 9 (14) 13 (21) 11.6 (P,0.01)
E9.5 9 84 21 (25) 38 (45) 14 (17) 11 (13) 1.46 (P.0.05)
(+) denotes wild type, (2) denotes either C-T-Neo or 2B-Neo.
doi:10.1371/journal.pone.0015887.t001
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we found the FL-Smn: D7Smn ratio to be 10-fold less in Smn
2B-Neo/2B-Neo
embryos (0.17860.022) as compared to Smn
C-T-Neo/C-T-Neo embryos
even though the amount of FL-Smn produced from either the
Smn
C-T-Neo or Smn
2B-Neo allele was not significantly different (p=0.43).
The change in ratio is due to the high levels of D7Smn transcripts that
Smn
2B-Neo/2B-Neo embryos produced and is consistent with the splicing
pattern and transcript ratios of SMN2 where the majority of SMN2
transcripts lack exon 7.
To correlate FL-Smn transcripts to Smn protein we performed
western blot analysis of single E9.5 embryos for each possible
genotype. We had difficulty detecting Smn in homozygous mutant
embryos, and the level varied between mutants of the same genotype
(Figure 3D). In general, the level of Smn correlated with the severity
of the mutant embryo when we retrospectively compared Smn levels
to our whole mount mutant embryo images (Figure 3D and Figure 2).
The level of Smn protein in Smn
C-T-Neo/C-T-Neo embryos ranged from
2–5% and in Smn
2B-Neo/2B-Neo embryos it was about 1–3%. This was
an unexpected finding based on our FL-Smn expression data from
Smn
C-T-Neo/C-T-Neo and Smn
2B-Neo/2B-Neo e m b r y o sa n dw a sm o s tl i k e l y
caused by the compromised physiological state of the SMA embryos,
a lackof stability of higher order Smncomplexesfromlow Smn levels
and transcriptional and/or translational hindrance from the floxed
pgk-neo cassette. Since the later was the only one that we could directly
test, we removed the floxed pgk-neo cassette from the germline using
homozygous EIIa-Cre transgenic mice that ubiquitously express Cre
recombinase very early in embryogenesis [36]. This increased Smn
protein levels from ,5% for homozygous Smn
C-T-Neo and Smn
2B-Neo
embryos to .30% for a single Smn
C-T allele and ,16% for a single
Smn
2B allele (data not shown and will be reported elsewhere).
Collectively, these results confirm that our Smn
C-T-Neo and Smn
2B-Neo
alleles are severe hypomorphs. They express very low amounts of
Smn due to the nature of our introduced mutations as well as the
presence of a floxed pgk-neo selection cassette that hinders Smn
expression. Thesealleles are ‘‘repairable’’and have the potential to be
used as inducibleSmn alleles that mimic SMN2 splicing.To determine
this directly, the following in vitro and in vivo experiments were
designed to address the ability of Smn
C-T-Neo and Smn
2B-Neo alleles to be
utilized as inducible Smn alleles by excision of the floxed pgk-neo
cassette.
Induction of Smn expression in vitro
We determined the ability of our progenitor alleles to induce
Smn levels through excision of the floxed pgk-neo cassette in vitro
using primary murine embryonic fibroblasts (MEFs). For these
experiments, we used our Smn
C-T-Neo allele in combination with a
tamoxifen (TM) inducible Cre allele, Cre
Esr1[37]. We established
and cultured MEF lines from two Smn
C-T-Neo/WT;Cre
Esr1 embryos
and compared untreated MEF cultures to those treated with TM.
Excision of floxed pgk-neo by Cre
Esr1 was monitored at the DNA
level by three primer PCR analysis (Figure 4A). The reaction
amplified all three possible Smn alleles: WT (470 bp), C-T-Neo
Figure 2. Whole mount analysis of embryos. Smn
2B-Neo or Smn
C-T-Neo heterozygotes were intercrossed and embryos obtained at either E9.5 or
E12.5 for whole-mount analysis and genotyping. (a–h) E9.5 Smn
C-T-Neo embryos. Heterozygotes (C-T-N/WT) are identical to wild type (WT/WT)
littermates. Homozygotes (C-T-N/C-T-N) are small but alive and larger than the Smn
2B-Neo/2B-Neo (2B-N/2B-N) homozygotes. (i–p) E12.5 Smn
C-T-Neo
embryos. Homozygotes are extremely small compared to controls and many are being reabsorbed as shown in panel (p). (a’–h’) E9.5 Smn
2B-Neo
embryos. Heterozygotes (2B-N/WT) are identical to wild type (WT/WT) littermates. Homozygotes (2B-N/2B-N) are developmentally retarded though
still alive with signs of lethality clearly present before this period in some embryos that did not allow for genotyping (Table 1). (i’–p’) E12.5 Smn
2B-Neo
embryos. All homozygous mutant embryos are undergoing resorption. Insets in o’ and p’ are magnified images of embryos in panel. Scale for all E9.5
embryos is 100 mM and for E12.5 200 mM.
doi:10.1371/journal.pone.0015887.g002
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PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15887Figure 3. Smn transcript analysis analysis of E9.5 embryos. (A) RT-PCR of E9.5 embryos comparing wild type, heterozygotes, and homozygotes.
Both FL-Smn and D7Smn transcripts are amplified from cDNA of mice that are heterozygous and homozygous for the mutant alleles. (B) Direct sequencing of
FL-Smn and D7Smn RT-PCR products derived from Smn
C-T-Neo/C-T-Neo mutants. The ‘‘T’’ denoted with an arrow above it, represents the C-T mutation. Dotted
line within exon6-8 sequence represents the junction between exon 6 and exon 8. (C)q R T - P C Rr e s u l t so fE 9 . 5e m b r y of o rFL-Smn and D7Smn transcripts.
FL-Smn transcripts for C-T-Neo and 2B-Neo were compared to wild type and heterozygous embryos within their own intercrosses and litters to control for
variability. Spinal cord (S.C.) cDNA from a 6-month D7/WT mouse was used to compare D7Smn transcripts from C-T-Neo and 2B-Neo heterozygous and
homozygous embryos. Wild type mice do not express D7Smn and are not shown on the graph. Each data point on the graphs represent individual embryos
and depiction of variability between embryos. (D) Immunoblot analysis of Smn expression from individual E9.5 embryos derived from Smn
C-T-Neo or Smn
2B-Neo
intercrosses. 15 times less protein was used for the controls to avoid overloading SMN while simultaneously detecting it in the mutants. Note the variation in
Smn levels from individual mutant embryos. Lower Smn levels correlated with more severe phenotypes (see Figure 2). To achieve this sensitivity, Smn
detection was performed on a Li-COR Odyssey infrared imaging system. Abbreviations: (WT) Smn
WT/WT,( C - T - N / W T )Smn
C-T-Neo/WT,( 2 B - N / W T )Smn
2B-Neo/WT,
(C-T-N/C-T-N) Smn
C-T-Neo/C-T-Neo,( 2 B - N / 2 B - N )Smn
2B-Neo/2B-Neo,( D7/WT) Smn
D7/WT.
doi:10.1371/journal.pone.0015887.g003
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demonstrated excision of the floxed pgk-neo cassette from the
Smn
C-T-Neo allele (Figure 4B, lanes 4 and 5). A low level of excision
was also noted in cells without TM treatment; we attributed this to
the previously reported ,0.1% spontaneous Cre activity that was
reported for this line [37] (Figure 4B, lanes 2 and 3). We then
correlated pgk-neo excision with an increase in FL-Smn expression
by directly sequencing RT-PCR products from treated and
untreated MEFs. A clearly discernable ‘‘T’’ nucleotide was present
in those cells treated with TM and absent in the untreated cultures
indicating an increase of Smn expression specifically from our
mutant allele (Figure 4C). This was substantiated and quantified
by qRT-PCR analysis which showed an 83% increase in FL-Smn
transcripts and a 30% reduction in D7Smn transcripts between
treated and untreated cultures (Figure 4D). Therefore, addition of
tamoxifen to cultures of Smn
C-T-Neo/WT;Cre
Esr1 MEFs increased FL-
Smn expression through excision of the floxed pgk-neo cassette in
Smn intron 7 and demonstrates the inducible nature of these alleles
in vitro.
The ability of our Smn alleles to be Cre responsive in post natal
somatic tissues was determined by single intraperitoneal (i.p.) injections
[9 mg/40 g body weight] of TM or vehicle (corn oil) to 2–4 month old
Smn
C-T-Neo/WT;Cre
Esr1 mice. They were euthanized five days post-
injection and DNA from kidney, spinal cord, skeletal muscle, forebrain
and cerebellum were used as template in PCR to determine floxed
pgk-neo excision. Vehicle injected Smn
C-T-Neo/WT;Cre
Esr1 mice had a low
level of DNA excision consistent with background levels of Cre
Esr1
(Figure 5A, lane 2). Smn
C-T-Neo/WT mice without Cre
Esr1 showed no
excision of the floxed pgk-neo cassette (Figure 5A, lane 3). In contrast,
excision occurred in all tissues examined from Smn
C-T-Neo/WT;Cre
Esr1
mice after a single i.p. injection (Figure 5A, lane 4), hence somatically
changing the Smn
C-T-Neo allele to a Smn
C-T allele.
Induction of Smn in Smn
C-T-Neo/C-T-Neo;Cre
Esr1 embryos
early, but not late, rescues embryonic lethality
The early lethality of Smn
C-T-Neo/C-T-Neo embryos was determined
to be caused by low Smn levels, thus we next sought to determine
when during development, if at all, we could increase Smn levels
and rescue the embryonic lethality phenotype. To this end we
crossed Smn
C-T-Neo/WT females to Smn
C-T-Neo/WT;Cre
Esr1 males in
order to produce Smn
C-T-Neo/C-T-Neo;Cre
Esr1 embryos. Without TM
Figure 4. Smn expression is efficiently induced from the Smn
C-T-Neo allele in vitro. Two independent primary MEF cells lines were derived
from double transgenic embryos (Smn
C-T-Neo/WT;Cre
Esr1). (A) Schematic of the Smn
C-T-Neo allele from exon 6 to exon 8. Arrows represent forward and
reverse primers used in the 3-plex PCR reaction to identify Smn
WT (640 & 637), Smn
C-T-Neo (638 & 637), and Smn
C-T (640 & 637) alleles. Primers 640 and
637 do not amplify a product in the presence of pgk-neo as the amplicon exceeds the time of elongation. (B) 3-plex PCR amplification of DNA from
MEF lines 1 and 2 treated for 1 hr with 1 mM tamoxifen (+TM). MEF lines 1 and 2 left untreated (-TM) showed a slight amount of background excision
(lanes 2 & 3); however, in the presence of tamoxifen (+TM), they readily amplify the Smn
C-T allele (lanes 4&5). Controls in lanes 6, 7, and 8 were E10.5
embryos harvested to show the indicated genotypes from crosses using germline transmitting Smn
C-T-Neo and Smn
C-T alleles. (C) RNA from untreated
(-TM) and induced (+TM) MEF cells were amplified by RT-PCR and FL-Smn transcripts directly sequenced. Induced MEFs (+TM) produced enough FL-
Smn transcripts from the mutant C-T allele that could be detected by direct sequencing. The arrow points out the C-T mutation in +TM treated
cultures. (D) qRT-PCR of FL-Smn and D7Smn from uninduced (-TM) and induced (+TM) cultures. Abbreviations: (TM) tamoxifen (C-T-N/WT;Cre+)
Smn
C-T-Neo/+;Cre
Esr1 (C-T-N/WT) Smn
C-T-Neo/+ (C-T/WT) Smn
C-T/+ (C-T-N/C-T) Smn
C-T-Neo/C-T.
doi:10.1371/journal.pone.0015887.g004
Table 2. qRT-PCR analysis of E9.5 Smn embryos.
E9.5 embryos Fl-Smn expression D7 Smn expression
WT/WT 1.0060.02
C-T-Neo/WT 0.6260.12 0.3360.06
2B-Neo/WT 0.5960.07 1.7260.23
C-T-Neo/C-T-Neo 0.2060.05 1.5660.22
2B-Neo/2B-Neo 0.1560.03 12.4463.28
D7/WT (6 month S.C.) 1.0060.10
S.C., spinal cord.
doi:10.1371/journal.pone.0015887.t002
Inducible Smn Alleles
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15887treatment these embryos should undergo complete resorption
between E12.5 and E15.5 (Figure 2 and Table 1). Pregnant
females were injected with TM [3 mg/40 g body weight] at either
E7.5 or E13.5. Only two litters (9 pups total) survived birthing
from 7 dams injected at E7.5 and visibly pregnant at late gestation.
Of these 9 pups, 1 was a Smn
C-T-Neo/C-T-Neo;Cre
Esr1 pup and of
similar size and appearance to its littermates. However, in both
litters the dams failed to lactate and fostering was unsuccessful.
Birthing and lactation problems are a known common side effect of
TM administration, especially when given early during pregnancy
[37]. To avert this problem we harvested embryos at E18.5, a late
point in gestation, and well after a stage in development (E15.5) in
Figure 5. Smn induction in adults and embryos from a single injection of tamoxifen. (A) DNA analysis of adult mice i.p. injected with
vehicle (corn oil) or TM (9 mg/40 g body weight) using the same 3-plex PCR reaction as shown in Figures 4A and B. Wild type mice (WT;Cre-) only
amplified the wild type allele (lane 1). Doubly transgenic mice (Smn
C-T-Neo/WT;Cre
Esr1) in the absence of TM (-TM) displayed a low basal level of pgk-neo
excision as has been previously reported for this Cre line [37]. In the absence of the Cre
Esr1 transgene, Smn
C-T-Neo/WT mice injected with TM could not
excise pgk-neo (lane 3), in all tissues analyzed, pgk-neo excision was only possible and efficient in the presence of Cre
Esr1 and TM (lane 4). (B) PCR
analysis of E18.5 embryos that received a single i.p. dose of TM (3 mg/40 g body weight) to the pregnant dam at E7.5 or E13.5 DNA was genotyped as
above to differentiate Smn
WT, Smn
C-T-Neo and Smn
C-T alleles. Arrows identify the appropriate amplicons. (C) Photomicrograph of E18.5 embryos
induced with TM at E7.5 or E13.5. Lines in photograph show where images were tiled together in Photoshop. (D) Western blot and semi-quantitative
densitometry of protein extracted from brain tissue of induced and control E18.5 embryos. A small amount of protein was able to be extracted from
severely deformed Smn
C-T-Neo/C-T-Neo embryos identified as ‘‘escapers’’ for comparison to induced Smn
C-T-Neo/C-T-Neo;Cre
Esr1 rescued embryos. Semi-
quantitative densitometry was performed on a separate blot using the same samples shown and normalized to b-tubulin, without the uninduced
mutant. Protein levels from induced homozygous embryos, Smn
C-T-Neo/C-T-Neo;Cre
ESR1, (0.760.10) was greater than Smn
WT/- (0.560.2). Abbreviations:
(WT) Smn wild type allele, (Cre+ and Cre-) presence or absence of Cre
Esr1, (C-T-N/WT) Smn
C-T-Neo/WT, (C-T-N/C-T-N) Smn
C-T-Neo/C-T-Neo, (C-T) Smn
C-T allele,
(C-T-Neo) Smn
C-T-Neo allele, (TM) tamoxifen.
doi:10.1371/journal.pone.0015887.g005
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C-T-Neo/C-T-Neo embryos had
previously been identified (Table 1). DNA prepared from yolk sacs
or tails was used for PCR-based genotyping with the same 3-plex
PCR assay used in Figures 4 and 5A. Thisallowed us to identify and
determine the efficiency of the floxed pgk-neo cassette excision. The
presence or absence of the Cre
Esr1 transgene was determined in a
separate reaction. In all embryos that carried both the Smn
C-T-Neo
allele and Cre
Esr1 transgene, the injection of TM induced excision of
floxed pgk-neo, thus somatically changing the Smn
C-T-Neo allele to a
Smn
C-T allele (Figure 5B, lanes 5-9). Smn induction of 4 litters at
E7.5 resulted in a total of 32 embryos at E18.5 and five were found
to be Smn
C-T-Neo/C-T-Neo;Cre
Esr1 embryos (Table 3). All five of these
embryos were viable, of similar size and indistinguishable from
control embryos (Figure 5C). In contrast, TM injection of 6 litters at
E13.5 resulted in no viable Smn
C-T-Neo/C-T-Neo;Cre
Esr1 embryos at
E18.5 (0/42) (Table 3). However, in each of these crosses we did
identify a Smn
C-T-Neo/C-T-Neo embryo that was negative for the Cre
Esr1
transgene although both were severely deformed, nonviable and
undergoing resorption (Figure 5C). Chi-square statistics were used
to compare the genetic ratios of induced embryos to expected
normal mendelian ratios with the assumption that Smn
C-T-Neo/C-T-Neo
embryos would not be present at E18.5. Genotype ratios from
embryos treated at E13.5 were not statistically significant from
expected ratios, p=0.84. However, the genotype ratios of embryos
treated at E7.5 were significant, p=0.05 (Table 3). Thus, increas-
ing Smn levels rescues the embryonic lethality phenotype of
Smn
C-T-Neo/C-T-Neo;Cre
Esr1 embryos when induced early, but not late
in development.
To quantify the level of Smn in these Smn
C-T-Neo/C-T-Neo;Cre
Esr1
embryos, we performed western blot analysis and compared them to a
series of control, age-matched embryos that titred Smn levels between
100% and 50%. In addition, we were able to extract a small amount of
protein from one of the non-viable Smn
C-T-Neo/C-T-Neo embryos for
comparison to ourinduced embryos (Figure 5D).However, withoutCre
mediated excision of the floxed pgk-neo cassette, Smn levels in this
embryo were below the limit of detection even though the loading
control, b–tubulin was visualized (Figure 5D). Densitometry was
performed on a separate western blot using the same samples for the
other genotypes (Figure 5C). The excision of the floxed pgk-neo cassette
in Smn
C-T-Neo/C-T-Neo;Cre
Esr1 +TM embryos increased Smn protein levels
to 70% of wild type expression (Figure 5D). This is greater than the
50% of Smn protein detected in heterozygous Smn null (Smn
WT/-)
embryos which develop normally and have a normal postnatal lifespan
(Figure 5D) [1]. Furthermore, this is greater than the level of Smn
expressed in our Smn
C-T-Neo and Smn
2B-Neo progenitor lines of mice that
have a normal lifespan and are without phenotype.
Discussion
We specifically designed the targeting vectors used in this study
to have a triple function so that a series of Smn alleles could be
generated. The first was the introduction of mutations within
known Smn exon 7 ESEs to mimic SMN2 exon 7 splicing and
attenuate Smn expression. The second was the placement of the
positive selection cassette within intron 7 with the aim of further
diminishing the amount of Smn generated from these targeted
alleles. It has previously been shown that selection cassettes located
within introns or regulatory regions, such as pgk-neo that we used
here, can hinder expression of targeted genes via transcriptional
and/or translation interference either by design ([38]; additional
examples cited in [39]) or inadvertently [40,41,42], which
sometimes proves to be serendipitous [42]. The level of
interference can be varied depending upon the orientation of the
selection cassette if it has cryptic splice donor and acceptor sites,
like the neo gene, [39] or they can be engineered. Here we used
pgk-neo in the inverted orientation to Smn transcription as the
cryptic splice sites were stronger. The third and final function of
our design was to flank pgk-neo with loxP sites so that it could be
removed with Cre recombinase. This allows the specific analysis of
our introduced mutations within the context of a minimally altered
genomic locus. Since the neo cassette hindered Smn expression as
we designed, our alleles can be used to induce Smn expression
while still mimicking SMN2 exon 7 alternative splicing. The
conceptual properties of this targeting design are applicable to
almost any gene targeting strategy and warrant consideration for
those embarking on new projects.
Our allelic targeting strategy provides the opportunity to
generate three mouse lines from each single allele. The first is
the original progenitor alleles, Smn
C-T-Neo and Smn
2B-Neo. The
second is these alleles in combination with a tissue specific or
inducible Cre transgene for future time and cell-specific induction
experiments. Finally, mouse lines possessing the point mutations
themselves, Smn
C-T and Smn
2B, can be produced. Here we have
focused on characterizing the first two lines of mice.
Mice heterozygous for the Smn
C-T-Neo and Smn
2B-Neo alleles were
normal. When homozygous, these alleles caused embryonic
lethality, even though full-length transcripts and small amounts
of Smn protein could be detected. This result illustrates once again
that a minimum amount of Smn is required by all cell types
[1,34,35,43,44], and this appears to be about 5% during
development in mice. Although we found no significant difference
in mendelian ratios of homozygous mutants for either allele at
E9.5, morphologically it was clear that the embryos were dead or
extremely growth retarded and their ability to develop corre-
sponded to their Smn levels. Embryonic lethality during this
period of development is commonly caused by potential failures in
gastrulation, defects in extra embryonic membrane functions such
as vasculogenesis or hematopoiesis and/or cardiovascular failure
[45]. Considering these possibilities, we were able to visualize
swollen pericardial sacs in several of our Smn
C-T-Neo/C-TNeo
homozygous mutants at E11.5 (data not shown) or E12.5 that
were not grossly deformed.
Table 3. Genotypes of Smn embryos at E18.5 exposed to tamoxifen at E7.5 or E13.5.
# of
litters
Total #
pups
WT
(%)
WT;Cre
(%)
C-T-N/WT
(%)
C-T-N/WT; Cre
(%)
C-T-N/C-T-N
(%)
C-T-N/C-T-N;
Cre (%) Unknown
E7.5 injection,
E18.5 harvest
4 32 3 (9) 5 (16) 3 (9) 11 (34) 1 (3) 5 (16) 4 (13)
E13.5 injection,
E18.5 harvest
6 42 6 (14) 6 (14) 10 (24) 10 (24) 1 (2) 0 (0) 9 (21)
(x
2, E7.5 injection p=0.051; E13.5 injection p=0.84).
doi:10.1371/journal.pone.0015887.t003
Inducible Smn Alleles
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e15887Functionally and molecularly the homozygous Smn
C-T-Neo/C-T-Neo
and Smn
2B-Neo/2B-Neo hypomorphs are less severe than Smn
D7/D7
homozygotes as they express small amounts of fully functional Smn
protein and live slightly longer (E12 and E9 vs E7) [34,35]. The
Smn
C-T-Neo/C-T-Neo homozygotes are generally less severe than the
Smn
2B-Neo/2B-Neo homozygotes due to the nature of the introduced
mutations within exon 7 since the C-T mutation produces more FL-
Smn transcripts than the 2B mutation. During the course of our
molecular analyses there were two unexpected observations. First,
we found that D7Smn transcripts from Smn
2B-Neo/2B-Neo embryos were
extremely high (12.4463.44) vs. heterozygous Smn
2B-Neo embryos
(1.7260.23). This may seem odd at first glance, but SMN together
with other proteins functions in the assembly of small nuclear
ribonucleoproteins (snRNPs), which are critical for pre-mRNA
splicing [46,47]. It has previously been demonstrated that low levels
of SMN cause changes in snRNP abundance and splicing
alterations [48,49,50], so it is possible that SMN regulates its own
splicing of SMN2 exon 7. In fact, Jodelka et al. (2010) [51] has
recently identified a feedback loop in which low SMN levels
exacerbate SMN2exon 7 skipping.Thisresulthelpsexplainthehigh
degree of D7Smn transcripts from our Smn
2B-Neo/2B-Neo embryos since
they produce only 1-3% Smn protein. The second observation was
the low amount of Smn protein (,5%) as compared to FL-Smn
transcripts (10-20%) in our homozygous embryos. We predict this is
caused by a combination of the degenerative state of the embryos,
lack of higher order Smn complexes that can stabilize the protein,
and the presence of the floxed pgk-neo cassette (as we designed),
which creates hybrid Smn/neo transcripts and exerts transcriptional
and translational repression. We show that removal of the pgk-neo
cassette is able to relieve this repression.
As progress in developing SMN-dependent therapies moves
forward, our understanding of when and where SMN is required
for severe, intermediate and mild forms of SMA becomes
important. This can be addressed using animal models since they
can be genetically manipulated. SMA has already been modeled in
a number of different organisms and each has its strengths [52,53],
but the most widely used to date have been SMA mouse models.
The mouse models fall into two categories:1) transgenics bred onto
Smn null or D7 backgrounds to rescue the embryonic lethality of
homozygous Smn mutants to produce varying degrees of SMA
severity, and 2) modifications of the endogenous Smn locus that
reduce Smn expression. One conditional allele of Smn has been
generated, a floxed allele of Smn exon 7, which can be combined
with varying Cre transgenes for the temporal or spatial depletion of
Smn. Although this is a very useful allele and conditional depletion
experiments have been done [34,43,44], SMA is due to a paucity
of Smn protein not complete absence of Smn protein. Currently
lacking, and which we begin to fulfill here, is a panel of different
Smn inducible alleles that can be used in future experiments to
address the cellular and temporal requirements of Smn induction
in varying SMA disease severities.
To validate the potential of Smn
C-T-Neo and Smn
2B-Neo to be
utilized as inducible alleles, we used Smn
C-T-Neo as a proof of
concept allele. Using Smn
C-T-Neo in combination with a tamoxifen
inducible Cre transgenic mouse, Cre
Esr1, we derived primary MEF
lines and proved that only in the presence of tamoxifen was Smn
induced. This illustrates the efficacy of Smn induction in vitro and
the potential of using these lines to establish Smn inducible culture
models. In addition, a single i.p. injection of tamoxifen was able to
excise the floxed pgk-neo cassette in somatic tissues of adult mice
and embryos. Hence, the alleles can be used in future somatic
experiments to assist in determining the cellular requirements of
Smn. This can be achieved through genetic crosses of tissue-
specific Cre lines or as shown here, through injections if the Cre
lines are tamoxifen inducible. In addition, if the Smn
C-T-Neo and/or
Smn
2B-Neo is used as the Smn mutant background in combination
with SMN2 transgenic mice to achieve postnatal survival, new
SMA models can potentially be generated with varying degrees of
severity. Thus, the timing requirements of Smn inductive therapies
could be addressed postnatally in severe, intermediate and mild
forms of SMA. We are currently working to develop these models
and determine this.
In a final experiment, we addressed whether the embryonic
lethality of Smn
C-T-Neo/C-T-Neo embryos could be rescued. We found
that we could, if induction occurred early, around gastrulation (E7.5),
but not late (E13.5), and the mutant embryos that were induced at
E7.5 expressed ,70% Smn protein. This level of Smn protein is well
above that of Smn
+/2 mice that have a normal lifespan [1] or
heterozygous SMA model mice [(SMN2)Ahmb89
+/+;Smn
+/2;J a x
strain 5024], which have no motor neuron loss and a normal lifespan
[54]. At this point our work is unable to address the dosage and
timing of Smn expression necessary to alleviate postnatal SMA
disease, which is the time period when all, but the very most severely
affected, SMA patients present with symptoms. However our results
are important as they are consistent with the few pharmacological or
gene therapy studies where a therapeutic window of opportunity to
demonstrate a survival or functional benefit exists in severe SMA
[15,17,29]. We all show that the earlier the intervention, the better
the outcome. The mounting results of these types of studies are
important points of consideration as clinical trials based on SMN-
inductive therapies are designed, especially for the most severe SMA
patients. It will be important for future studies to add and extend this
work. For example, a paramount point is whether SMN inductive
therapies can provide benefit during the lag/plateau phase of disease
or prevent further deterioration of function from the point of
treatment. We believe that the alleles we have generated here will be
useful in developing the appropriate models to answer this question.
In conclusion, the gene targeting strategy that we utilized is
applicable to almost all gene targeting projects. The strategy
provides the potential to generate multiple lines of mice, including
an inducible allele, from a single targeting event for the cost of
extra effort put into the planning stage of vector design. As proof,
we generated an allelic series of Smn mice. They produce small
amounts of Smn, mimic SMN2 splicing and are inducible. While
these are the first inducible Smn alleles to be described in the
literature, other groups are also working to generate inducible Smn
mice using different strategies such as Tet-on/off systems or other
Cre-inducible alleles. As proven with the various transgenic models
of SMA, all will play important and complimentary roles as we
move forward to understand Smn function in health and disease,
and progress towards developing a therapy for SMA.
Materials and Methods
Ethics Statement
All studies performed on mice were in accordance with the
Institutional Animal Care and Use Committee regulations in place
at Children’s Memorial Research Center and specifically ap-
proved under protocols 2007-15, 2006-22 and 2008-03.
Construction of targeting vectors and generation of
Chimeras
The replacement vectors, p(Smn
C-T-Neo) and p(Smn
2B-Neo) are
shown schematically in Figure 1A. The total length of homology
between the targeting vector and the endogenous Smn locus is
6.5 kb; the long arm is 5.0 kb and the short arm is 1.5 kb. The
positive selection cassette, flox-pgk-neo was inserted into the unique
BamHI site 180 bp distal to exon 7. This was done to increase the
Inducible Smn Alleles
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transition in exon 7 or the 2B mutation (GGA-TTT) in exon 7,
since recombination is unlikely to occur within such a short
distance between our modification and the positive selection
cassette. The mutations were introduced via site directed
mutagenesis of a smaller fragment and then re-subcloned into
the targeting construct to avoid potential mutations generated by
PCR. In total, after Cre excision of the pgk-neo cassette, ,90 bp
will remain, of which, 34 bases correspond to the remaining loxP
site. The 90 bp of sequence is located sufficiently distal to exon 7
and should not affect regulation or processing of the Smn
C-T-Neo
and Smn
2B-Neo transcripts. The targeting constructs were electro-
porated into 129 ES cells and 4 independent homologous
recombinant clones for each construct were identified. Two from
each construct were used to generate chimeras by microinjecting
ES cells into C57Bl/6 blastocysts.
Mice and Animal Care
Animals were kept in a controlled vivarium at 25uC and 50%
humidity in a 12 hour light/12 hour dark photoperiod and
monitored for health. Colonies were maintained by breeding
mice heterozygous for the Smn mutant alleles. The official name
for Smn
C-T-Neo/+ mice is Smn
tm2Cdid. It is being placed at The Jackson
laboratory in both C57BL/6 and FVB/N genetic backgrounds but
currently lacks official strain designation. The official name of the
Smn
2B-Neo/+ mice is Smn
tm1Cdid and it is also being placed at The
Jackson Laboratory in both C57BL/6 (Jax strain 008838) and
FVB/N (JAX 008837) genetic backgrounds. The lines will be
made available once they are on congenic C57Bl/6 and FVB/N
genetic backgrounds.
Genotyping reactions
All PCR and RT-PCR experiments were performed on an
Eppendorf MastercyclerH. Smn
C-T-Neo/+ and Smn
2B-Neo/+ adults
(Table 1) were genotyped using forward primer #638 (59-AATGTG
TGC GAGGCCAGAGG-39) found within the PGK promoter and
reverse primer #637 (59-TTTGGCAGACTT TAGCAGGGC-39)
within intron 7 multiplexed with an internal control set of primers
that amplified Smn exon 4 using primers #379 (59-A G G C G T
TGAATGACATTCTC) and #380 (59-GCCATACAAAGTGTT-
CACAC). Reaction conditions: 94uC/45 sec, 60uC/45 sec, 72uC/
45 sec, 35 cycles. C-T-Neo or 2B-Neo alleles produced a 519 bp
amplicon and the internal control amplified a 697 bp product. PCR
products were resolved on a 1.5% agarose gel.
Smn
C-T-Neo and Smn
2B-Neo allelic embryos (Table 1) were
genotyped using a three primer PCR reaction. The primers
include Smn intron 6 forward, #721 (59-TATCACTAAG-
TTGGGCGA AAG GG-39), Smn intron 7 reverse, #636 (59-
TTTGGCAGACTT TAGCAGGGC-39), and PGK promoter
reverse primer #638 (59-AATGTGTGCGAGGCCAGAGG-39).
Reaction conditions: 94uC/45 sec, 64uC/45 sec, 72uC/1 min, 35
cycles. The product sizes for the C-T-Neo and 2B-Neo alleles are
519 bp and 700 bp for the WT allele.
Analysis of pgk-neo excision was performed on MEF colonies,
induced adults and embryos using a 3- primer PCR reaction with
primers #638, intron 6 forward primer # 640, (59- AAC-
TCCGGGTCCTCCTTCCT) and #637 to amplify Smn
WT
(470 bp), Smn
C-T-Neo (500 bp), and Smn
CT (577 bp) alleles. Cre
amplification utilized forward primer #162 (59-CGCCGCA-
TAACC AGTGAAAC-39) and reverse primer #163 (59-ATGTC-
CAATTTACTGACCG-39) to amplify a 335 bp fragment.
Smn exon 7 was amplified for direct sequencing using primers
forward intron 6 primer #58 (59-CCTCCTTCCTCCTCATCT-
CAG-39) and reverse intron 7 primer #62 (59- AATTATA-
CAAAAGGTAAAATTAGC) under standard cycling conditions.
PCR products were purified with Montage PCR clean up column
(Millipore) and sequenced using intron 6 primer #59 (59-TCC-
AGCCGGGCTTGAATT).
RNA Transcript Analysis
RNA was extracted from tissues using TRIzol reagent (Invitro-
gen) in accordance with the manufacturer’s directions. Samples
were then treated with TURBO DNA-free reagents (Ambion) and
first strand cDNA was prepared using SuperScript
TM II Reverse
Transcriptase (Invitrogen) and random hexamer primers (Roche,
Nutley, NJ) according to the manufacturer.
The RT-PCR reaction to amplify both full length Smn and
D7Smn mRNA used primers 455 and 495. All reactions used
100 ng cDNA in a mix of 10X buffer (20 mM Tris-HCl (pH 8.4),
50 mM KCl), 200 mM dNTP mix, 3 mM MgCl2, 7.5pM primers,
and 1U taq polymerase. RT-PCR conditions were as follows:
94uC/45 sec, 60uC/45 sec, 72uC/45 sec, 30 cycles. RT-PCR
reaction used to identify the full length products of homozygous
mutant embryos (Fig. 3A) was performed using an exon 5 forward
primer #741 (59- TCCCTTCAGGACCACCAATA) and an
exon 8 reverse primer #495. Reaction conditions were: 94uC/
45 sec, 60uC/45 sec, 72uC/45 sec, 35 cycles. FL-Smn transcripts
from MEFs that were used as a template in sequencing were
amplified using primers #741 and# 495. D7Smn transcripts were
amplified using exon 5-6 forward primer #490 (59-CTTCAG-
GACCACCAATAA TC) and exon 6-8 reverse primer, #500 (59-
GACAGAGCTGAACAATAT). Both were sequenced with
primer #490.
qRT-PCR was performed on cDNA prepared as described above.
All reactions were performed in triplicate in a 20 ul final reaction
volume. Since the assay on demand primer and probe available from
ABI for Smn exon 7 are too close or overlap the C-T and 2B
mutations and could hinder interpretation of results, we designed and
validated FL-Smn and D7Smn assays to specifically amplify Smn
transcripts with similar efficiencies between the WT, C-T and 2B
mutations and not cross react with human SMN. Once validated
these assays were prepared by ABI in a 20X mastermix to be similar
to an assay on demand. FL-Smn was amplified and detected with
primer #ABI-1, Smn678F (59-TGGCTACCACACTGGCTAC-
TATATG), primer #ABI-2, Smn678R (59- GACACCCCATC-
TCCTGAGACA) and probe ABI-3, Smn678M1 (6FAM-CATA-
CAAATTAAGAAGTTCAGC). D7Smn transcripts were amplified
and detected with primer #ABI-4, Smn_EX6_8F (59- GGCAG-
TATGCTAATCTCTTGGTACA), primer #ABI-5, Smn_EX6_
8R (59- CGACACCCCATCTCCTGAGA) and probe #ABI-6,
Smn_EX6_8M1 (59- 6FAM-CAGAGCTGAACCATATAGTAG-
C). mGapdh On Demand Assay (Applied Biosystems) was used as an
internal control for normalizing data. All qRT-PCR reactions were
run using an Applied Biosytems 7500 Fast Real-Time PCR System
utilizing the following conditions: 1 cycle: 2 min 50uC, 1 cycle:
10 min 95uC, 40 cycles: 15 sec 95uC, 1 min 60uC. All data was
analyzed using the DDCt method.
Protein isolation, western blot and densitometry
Tissues and embryos were homogenized as previously described
[55]. Primary antibodies used were mouse monoclonal antibodies
to Smn (BD Translabs) at 1:5,000 and b-tubulin at 1:20,000.
Polyclonal rabbit actin at 1:1,000. The secondary antibody, goat
anti-mouse (BioRad) or goat anti-rabbi (BioRad) were used at
1:10,000. Membranes were exposed to chemiluminescence (ECL
Western Blotting Detection Reagents, Amersham Biosciences) and
developed on Kodak film. Blots were imported into Adobe
Photoshop using Microtek 1000XL scanner and quantified
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Odyssey System was used to quantify embryo extracts in Figure 3
according to the instructions of the manufacturer (Li-Cor
Biosciences). Briefly, proteins were resolved on a 4–12% Bis Tris
NuPage pre-cast gel system using MES running buffer and
transferred to nitrocellulose using the I-Blot transfer system
(Invitrogen). Bound antibodies were detected using IR-
Dye800CW-conjugated goat anti-mouse IgG (Li-Cor). The
intensity of each band was measured and normalized to that
obtained from Tubulin.
Whole Mount Embryo Images
Pregnant female mice were sacrificed by CO2 asphyxiation
followed with cervical dislocation. Embryos at either E9.5, E12.5
or E18.5 were captured on a Leica upright dissecting microscope
and digital camera at 2.0X, 1.0X, and 0.8X magnifications
respectively. Embryos at E11.5 were captured at 1.0X. Photo-
graphs were taken at a 300dpi, 8 bit/channel quality.
pgk-neo excision by TM in MEFs
Pregnant females were sacrificed with CO2 asphyxiation at 14.5
days post coitum (dpc). Embryos were individually eviscerated and
rinsed in 1X PBS for MEF preparation. Yolk sac was collected for
DNA to identify Smn
C-T-Neo/+;Cre
Esr1 embryos. Embryos were finely
minced with a straight edge razor and incubated in trypsin at
37uC. Debris were removed by resuspending cells in 15cc tube
containing cell growing media (Earle’s alpha-MEM, 10% FBS, 1%
pen/strep, 1% non-essential amino acids, 1% L-glutamine) and
allowing large debris to collect at the bottom. The supernatant was
plated and cells were passaged 4 times before those with the
genotype Smn
C-T-Neo/+;Cre
Esr1 were used for experiments. TM
(1 mM) was added to cultures for 1 hr to induce CRE activity.
Control cells received no TM. After 24 hours cells were harvested
for DNA and RNA as previously described for tissue samples.
pgk-neo excision by TM in adult and embryonic mice
Injection of TM to both adult and embryo used here, were
carried out as previously described [37]. TM was diluted to
10 mg/ml in corn oil. Adults were injected with 9 mg TM/40 g
body weight and sacrificed five days later. Tissues harvested
included spinal cord, skeletal muscle (gastrocnemius and quadri-
ceps), cortex, cerebellum, heart and kidney. Both DNA and RNA
were extracted as previously described. For embryonic induction,
pregnant females were injected at 7.5 dpc or 13.5 dpc with 3 mg
TM/40 g of body weight. At 18.5 dpc, females were sacrificed
with CO2 asphyxiation and embryos dissected individually. From
each embryo the lung was harvested for DNA and the remainder
flash frozen in liquid nitrogen and stored at 280uC.
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